Jianhai Tech Acquires Changsha Siyuan for Tens of Millions, Dominating Over 70% of the Post-Diagnosis Disease Management Market

On November 30, 2020, Hangzhou Jianhai Science and Technology Co., Ltd. (hereinafter referred to as “Jianhai Tech”) and Changsha Siyuan Technology Industry Co., Ltd. (hereinafter referred to as “Changsha Siyuan”) announced the execution of a definitive agreement, whereby Jianhai Tech formally acquired Changsha Siyuan. This acquisition secured Jianhai Tech a market share exceeding 70% in post-diagnosis disease management and enabled its active expansion into the development of digital therapeutics platforms and clinical validation of single-disease digital therapeutics.

Wang Jian, Founder and CEO of Jianhai Technology, stated: “Over the past five years, Jianhai Technology’s post-consultation disease management system has been deployed in more than 400 hospitals, including over 250 Grade III Class A hospitals. With this acquisition, the company’s hospital client base will increase to 700. Jianhai Technology will accelerate the use of AI technology to drive the development of the post-consultation disease management market, break through key bottlenecks in post-consultation disease management, reduce disease management costs, and improve the quality of disease management. Meanwhile, this will help customers on a broader scale recognize the advantages of the third-party co-construction model for post-consultation disease management, facilitating a transition from AI software output to integrated post-consultation disease management solutions.”

In 2021, Jianhai Technology aims to serve over 1,000 clients in post-diagnosis disease management and achieve large-scale AI substitution for disease management tasks, thereby liberating doctors and nurses. The company will actively develop knowledge graphs for single-disease management and conduct clinical validation. Looking ahead, Jianhai aspires to become a digital therapeutics platform for post-diagnosis disease management, establishing a comprehensive, streamlined system encompassing digital therapeutics solution design, software support, CRO-led clinical validation, and market promotion, thereby supporting industry development.

Hangzhou Jianhai Science and Technology Co., Ltd., founded in 2015, has long adhered to its mission of “making care a potent remedy.” By leveraging four entry-level applications, the company has established the foundational infrastructure for hospital-based digital therapeutics platforms. These applications include the “AI Full-Course Disease Management Platform,” the “AI Tiered Diagnosis and Treatment Platform for Chronic Diseases,” the “Smart Health Education 3.0 Platform,” and “Security X.” Supported by two core pillars—AI-driven disease management and third-party services—the company enhances efficiency in the digital therapeutics industry, establishes evaluation frameworks for digital therapeutics, reduces market entry costs, and provides customers with integrated digital therapeutics solutions.

Changsha Siyuan has accumulated nearly 15 years of technical expertise and industry reputation in the fields of hospital patient follow-up and clinical research. It collaborates with over 250 hospitals, including more than 100 Grade III Class A hospitals, and partners with the Second Xiangya Hospital of Central South University, dedicated to providing informatics solutions and software services for hospital patient follow-up and clinical research.

This acquisition positions Jianhai Technology as the leading enterprise in China’s post-diagnosis disease management market. The two parties will forge a powerful alliance in areas such as post-hospital care, patient follow-up, and clinical research, laying the foundation for Jianhai Technology to build the premier digital therapeutics platform.